nodes	percent_of_prediction	percent_of_DWPC	metapath
Methantheline—HRH2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0768	0.0768	CbGpPWpGaD
Methantheline—HRH2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0655	0.0655	CbGpPWpGaD
Methantheline—HRH2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0636	0.0636	CbGpPWpGaD
Methantheline—HRH2—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0592	0.0592	CbGpPWpGaD
Methantheline—HRH2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0551	0.0551	CbGpPWpGaD
Methantheline—HRH2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0535	0.0535	CbGpPWpGaD
Methantheline—HRH2—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0498	0.0498	CbGpPWpGaD
Methantheline—HRH2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0415	0.0415	CbGpPWpGaD
Methantheline—CHRM1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0375	0.0375	CbGpPWpGaD
Methantheline—HRH2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0349	0.0349	CbGpPWpGaD
Methantheline—CHRM1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.032	0.032	CbGpPWpGaD
Methantheline—CHRM1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.031	0.031	CbGpPWpGaD
Methantheline—CHRM1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0289	0.0289	CbGpPWpGaD
Methantheline—CHRM1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0269	0.0269	CbGpPWpGaD
Methantheline—CHRM1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0261	0.0261	CbGpPWpGaD
Methantheline—CHRM1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0243	0.0243	CbGpPWpGaD
Methantheline—CHRM1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0202	0.0202	CbGpPWpGaD
Methantheline—CHRM1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.017	0.017	CbGpPWpGaD
Methantheline—HRH2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.0126	0.0126	CbGpPWpGaD
Methantheline—HRH2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.0123	0.0123	CbGpPWpGaD
Methantheline—HRH2—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.0114	0.0114	CbGpPWpGaD
Methantheline—HRH2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.0108	0.0108	CbGpPWpGaD
Methantheline—HRH2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.0105	0.0105	CbGpPWpGaD
Methantheline—HRH2—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00979	0.00979	CbGpPWpGaD
Methantheline—HRH2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00825	0.00825	CbGpPWpGaD
Methantheline—HRH2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00801	0.00801	CbGpPWpGaD
Methantheline—HRH2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00801	0.00801	CbGpPWpGaD
Methantheline—CHRM1—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.00753	0.00753	CbGpPWpGaD
Methantheline—HRH2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00746	0.00746	CbGpPWpGaD
Methantheline—CHRM1—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.00731	0.00731	CbGpPWpGaD
Methantheline—HRH2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00686	0.00686	CbGpPWpGaD
Methantheline—CHRM1—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.00681	0.00681	CbGpPWpGaD
Methantheline—CHRM1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00617	0.00617	CbGpPWpGaD
Methantheline—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00599	0.00599	CbGpPWpGaD
Methantheline—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00558	0.00558	CbGpPWpGaD
Methantheline—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00528	0.00528	CbGpPWpGaD
Methantheline—HRH2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00522	0.00522	CbGpPWpGaD
Methantheline—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00513	0.00513	CbGpPWpGaD
Methantheline—CHRM1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00505	0.00505	CbGpPWpGaD
Methantheline—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00478	0.00478	CbGpPWpGaD
Methantheline—HRH2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00466	0.00466	CbGpPWpGaD
Methantheline—HRH2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00452	0.00452	CbGpPWpGaD
Methantheline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00452	0.00452	CbGpPWpGaD
Methantheline—HRH2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00423	0.00423	CbGpPWpGaD
Methantheline—HRH2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00422	0.00422	CbGpPWpGaD
Methantheline—HRH2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00411	0.00411	CbGpPWpGaD
Methantheline—CHRM1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00402	0.00402	CbGpPWpGaD
Methantheline—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00391	0.00391	CbGpPWpGaD
Methantheline—CHRM1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00391	0.00391	CbGpPWpGaD
Methantheline—HRH2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00383	0.00383	CbGpPWpGaD
Methantheline—CHRM1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00364	0.00364	CbGpPWpGaD
Methantheline—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00335	0.00335	CbGpPWpGaD
Methantheline—HRH2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00295	0.00295	CbGpPWpGaD
Methantheline—HRH2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00268	0.00268	CbGpPWpGaD
Methantheline—CHRM1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00255	0.00255	CbGpPWpGaD
Methantheline—HRH2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.0025	0.0025	CbGpPWpGaD
Methantheline—HRH2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00243	0.00243	CbGpPWpGaD
Methantheline—CHRM1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00227	0.00227	CbGpPWpGaD
Methantheline—HRH2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00226	0.00226	CbGpPWpGaD
Methantheline—CHRM1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00221	0.00221	CbGpPWpGaD
Methantheline—CHRM1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00206	0.00206	CbGpPWpGaD
Methantheline—CHRM1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00206	0.00206	CbGpPWpGaD
Methantheline—CHRM1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.002	0.002	CbGpPWpGaD
Methantheline—CHRM1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00187	0.00187	CbGpPWpGaD
Methantheline—HRH2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.00158	0.00158	CbGpPWpGaD
Methantheline—CHRM1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00144	0.00144	CbGpPWpGaD
Methantheline—CHRM1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00131	0.00131	CbGpPWpGaD
Methantheline—CHRM1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00122	0.00122	CbGpPWpGaD
Methantheline—CHRM1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00118	0.00118	CbGpPWpGaD
Methantheline—CHRM1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.0011	0.0011	CbGpPWpGaD
Methantheline—CHRM1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000773	0.000773	CbGpPWpGaD
